191 related articles for article (PubMed ID: 36322453)
1. Role of Pharmacogenomics in the Efficacy and Safety of Thiopurines in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
Gutiérrez-Valencia M; Leache L; Saiz LC; Beloqui JJ; Barajas M; Vicuña M; Erviti J
J Clin Gastroenterol; 2023 Aug; 57(7):671-685. PubMed ID: 36322453
[TBL] [Abstract][Full Text] [Related]
2. Time to incorporate preemptive NUDT15 testing before starting thiopurines in inflammatory bowel disease in Asia and beyond: a review.
Desai D; Jena A; Sharma V; Hibi T
Expert Rev Clin Pharmacol; 2023; 16(7):643-653. PubMed ID: 37387532
[TBL] [Abstract][Full Text] [Related]
3. TPMT and NUDT15 Variants Predict Discontinuation of Azathioprine for Myelotoxicity in Patients with Inflammatory Disease: Real-World Clinical Results.
Dickson AL; Daniel LL; Zanussi J; Dale Plummer W; Wei WQ; Liu G; Reese T; Anandi P; Birdwell KA; Kawai V; Cox NJ; Dupont WD; Hung AM; Feng Q; Stein CM; Chung CP
Clin Pharmacol Ther; 2022 Jan; 111(1):263-271. PubMed ID: 34582038
[TBL] [Abstract][Full Text] [Related]
4. Predictive role of NUDT15 variants on thiopurine-induced myelotoxicity in Asian inflammatory bowel disease patients.
Sutiman N; Chen S; Ling KL; Chuah SW; Leong WF; Nadiger V; Tjai M; Choon Kong CS; Schwender BJ; Chan W; Shim HH; Lim WC; Khor CC; Cheung YB; Chowbay B
Pharmacogenomics; 2018 Jan; 19(1):31-43. PubMed ID: 29210335
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping.
Kakuta Y; Kinouchi Y; Shimosegawa T
J Gastroenterol; 2018 Feb; 53(2):172-180. PubMed ID: 29192347
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of polymorphisms in thiopurine metabolism and association with adverse outcomes: a South Asian region-specific systematic review and meta-analysis.
Jena A; Jha DK; Kumar-M P; Kasudhan KS; Kumar A; Sarwal D; Mishra S; Singh AK; Bhatia P; Patil A; Sharma V
Expert Rev Clin Pharmacol; 2021 Apr; 14(4):491-501. PubMed ID: 33682590
[No Abstract] [Full Text] [Related]
7. Azathioprine dose tailoring based on pharmacogenetic information: Insights of clinical implementation.
Díaz-Villamarín X; Fernández-Varón E; Rojas Romero MC; Callejas-Rubio JL; Cabeza-Barrera J; Rodríguez-Nogales A; Gálvez J; Morón R
Biomed Pharmacother; 2023 Dec; 168():115706. PubMed ID: 37857254
[TBL] [Abstract][Full Text] [Related]
8. TPMT and NUDT15 polymorphisms in thiopurine induced leucopenia in inflammatory bowel disease: a prospective study from India.
Grover N; Bhatia P; Kumar A; Singh M; Lad D; Mandavdhare HS; Samanta J; Prasad KK; Dutta U; Sharma V
BMC Gastroenterol; 2021 Aug; 21(1):327. PubMed ID: 34425754
[TBL] [Abstract][Full Text] [Related]
9. Comparison of
Wang HH; He Y; Wang HX; Liao CL; Peng Y; Tao LJ; Zhang W; Yang HX
World J Gastroenterol; 2018 Feb; 24(8):941-948. PubMed ID: 29491687
[TBL] [Abstract][Full Text] [Related]
10. NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study.
Kakuta Y; Kawai Y; Okamoto D; Takagawa T; Ikeya K; Sakuraba H; Nishida A; Nakagawa S; Miura M; Toyonaga T; Onodera K; Shinozaki M; Ishiguro Y; Mizuno S; Takahara M; Yanai S; Hokari R; Nakagawa T; Araki H; Motoya S; Naito T; Moroi R; Shiga H; Endo K; Kobayashi T; Naganuma M; Hiraoka S; Matsumoto T; Nakamura S; Nakase H; Hisamatsu T; Sasaki M; Hanai H; Andoh A; Nagasaki M; Kinouchi Y; Shimosegawa T; Masamune A; Suzuki Y;
J Gastroenterol; 2018 Sep; 53(9):1065-1078. PubMed ID: 29923122
[TBL] [Abstract][Full Text] [Related]
11. NUDT15: A bench to bedside success story.
Moyer AM
Clin Biochem; 2021 Jun; 92():1-8. PubMed ID: 33675810
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of pretreatment screening for NUDT15 defective alleles.
Zarca K; Chansavang A; Loriot MA; Durand-Zaleski I; Pallet N
Pharmacogenet Genomics; 2020 Oct; 30(8):175-183. PubMed ID: 32433339
[TBL] [Abstract][Full Text] [Related]
13. A pharmacogenetics study of TPMT and ITPA genes detects a relationship with side effects and clinical response in patients with inflammatory bowel disease receiving Azathioprine.
Zabala-Fernández W; Barreiro-de Acosta M; Echarri A; Carpio D; Lorenzo A; Castro J; Martínez-Ares D; Pereira S; Martin-Granizo I; Corton M; Carracedo A; Barros F
J Gastrointestin Liver Dis; 2011 Sep; 20(3):247-53. PubMed ID: 21961091
[TBL] [Abstract][Full Text] [Related]
14. NUDT15 C415T variant compared with TPMT genotyping in predicting azathioprine-induced leucopenia: prospective analysis of 1014 inflammatory bowel disease patients in India.
Banerjee R; Ravikanth VV; Pal P; Bale G; Avanthi US; Goren I; Girish BG; Mitnala S; Reddy DN
Aliment Pharmacol Ther; 2020 Dec; 52(11-12):1683-1694. PubMed ID: 33111378
[TBL] [Abstract][Full Text] [Related]
15. Additive effects of TPMT and NUDT15 on thiopurine toxicity in children with acute lymphoblastic leukemia across multiethnic populations.
Maillard M; Nishii R; Yang W; Hoshitsuki K; Chepyala D; Lee SHR; Nguyen JQ; Relling MV; Crews KR; Leggas M; Singh M; Suang JLY; Yeoh AEJ; Jeha S; Inaba H; Pui CH; Karol SE; Trehan A; Bhatia P; Antillon Klussmann FG; Bhojwani D; Haidar CE; Yang JJ
J Natl Cancer Inst; 2024 May; 116(5):702-710. PubMed ID: 38230823
[TBL] [Abstract][Full Text] [Related]
16. Preemptive NUDT15 genotyping: redefining the management of patients with thiopurine-induced toxicity.
Shah SAV; Paradkar MU; Desai DC; Ashavaid TF
Drug Metab Pers Ther; 2018 Mar; 33(1):57-60. PubMed ID: 29470173
[TBL] [Abstract][Full Text] [Related]
17. ITPA polymorphisms do not predict additional risk beyond TPMT and NUDT15 for thiopurine-induced cytopenia in inflammatory bowel disease.
Jena A; Grover N; Bhatia P; Singh M; Lad D; Prasad KK; Singh H; Dutta U; Sharma V
Rev Gastroenterol Mex (Engl Ed); 2024; 89(1):25-30. PubMed ID: 36707393
[TBL] [Abstract][Full Text] [Related]
18. Impact of NUDT15 genetics on severe thiopurine-related hematotoxicity in patients with European ancestry.
Schaeffeler E; Jaeger SU; Klumpp V; Yang JJ; Igel S; Hinze L; Stanulla M; Schwab M
Genet Med; 2019 Sep; 21(9):2145-2150. PubMed ID: 30728528
[TBL] [Abstract][Full Text] [Related]
19. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update.
Relling MV; Schwab M; Whirl-Carrillo M; Suarez-Kurtz G; Pui CH; Stein CM; Moyer AM; Evans WE; Klein TE; Antillon-Klussmann FG; Caudle KE; Kato M; Yeoh AEJ; Schmiegelow K; Yang JJ
Clin Pharmacol Ther; 2019 May; 105(5):1095-1105. PubMed ID: 30447069
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic determinants of thiopurines in an Indian cohort.
Naushad SM; Janaki Ramaiah M; Kutala VK; Hussain T; Alrokayan SA
Pharmacol Rep; 2021 Feb; 73(1):278-287. PubMed ID: 32935219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
